Muestra la distribución de la producción WoS, Scopus y SciELO del autor.
Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.
Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl
Consultas o comentarios: productividad@anid.cl
| Firmas del autor | |
| Nombre | MOLT, FERNANDO |
| Género | Hombre |
| Área Principal WOS | Neurosciences; Psychiatry; Clinical Neurology; |
| Afiliación Principal | Universidad Católica Del Norte |
Publicaciones en Chile
Citas Totales
Afiliaciones Chilenas
Periodo registrado: 2008 - 2025
| WOS | #Pub |
|---|---|
| Neurosciences | 4 |
| Psychiatry | 3 |
| Clinical Neurology | 3 |
| Genetics & Heredity | 2 |
| Urology & Nephrology | 2 |
| Endocrinology & Metabolism | 2 |
| Biochemistry & Molecular Biology | 1 |
| Medicine, Research & Experimental | 1 |
| Scopus | #Pub |
|---|---|
| Neurology (Clinical) | 5 |
| Psychiatry And Mental Health | 3 |
| Surgery | 3 |
| Nephrology | 2 |
| Neurology | 2 |
| Transplantation | 2 |
| Biochemistry, Genetics And Molecular Biology (Miscellaneous) | 1 |
| Endocrinology, Diabetes And Metabolism | 1 |
| Internal Medicine | 1 |
| SciELO | #Pub |
|---|---|
| Health Sciences | 3 |
| Año | Firma | Institución (Incites asoc.) | H Index | Average Percentile | Impact Citation | Impact Relative World | Impact Journal Normalized Citation | Impact Category Normalized Citation | Percentage Cited | Percentage Top 1 | Percentage Top 10 | Percentage Journal Q1 | Percentage Journal Q2 | Percentage Journal Q3 | Percentage Journal Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2019 | Molt, Fernando | Universidad Catolica del Norte | 0.0 | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 |
| Palabra Clave | #Pub |
|---|---|
| multiple sclerosis | 3 |
| fabry disease | 3 |
| enzyme replacement therapy | 3 |
| sleep disorders | 2 |
| pandemic | 2 |
| sleep disease | 2 |
| therapy | 2 |
| consensus | 2 |
| autoimmune disease | 2 |
| nmdar | 1 |
| relapse | 1 |
| neuromyelitis-optica | 1 |
| nmosd | 1 |
| neuromyelitis optica spectrum disorder | 1 |
| pandemias | 1 |
| prevalence | 1 |
| professionals | 1 |
| recommendations | 1 |
| registry | 1 |
| mogad | 1 |
| rituximab | 1 |
| satralizumab | 1 |
| trastornos del sueño | 1 |
| trastornos del sueño-vigilia | 1 |
| trial | 1 |
| young adult | 1 |
| females | 1 |
| alpha-galactosidase | 1 |
| covid-19 | 1 |
| demyelinating disease | 1 |
| demyelinating diseases | 1 |
| diagnostic delay | 1 |
| disability | 1 |
| disasters | 1 |
| enfermedades autoinmunes | 1 |
| epidemiology | 1 |
| esclerosis múltiple | 1 |
| myelin oligodendrocyte glycoprotein | 1 |
| impact | 1 |
| insomnia | 1 |
| involvement | 1 |
| latin america | 1 |
| management | 1 |
| mental-health | 1 |
| mog | 1 |
| adults | 1 |
| mri | 1 |
Descargar
Descarga los datos de esta página (formato JSON).
Descargar
Descarga los datos de esta página como un archivo Excel.
